CN112313220A - Pd-l1拮抗剂化合物 - Google Patents

Pd-l1拮抗剂化合物 Download PDF

Info

Publication number
CN112313220A
CN112313220A CN202080003296.6A CN202080003296A CN112313220A CN 112313220 A CN112313220 A CN 112313220A CN 202080003296 A CN202080003296 A CN 202080003296A CN 112313220 A CN112313220 A CN 112313220A
Authority
CN
China
Prior art keywords
alkylene
compound
alkyl
added
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080003296.6A
Other languages
English (en)
Other versions
CN112313220B (zh
Inventor
李磐
徐贝帝
温俏冬
冯恩光
王骥
路杨
周瑜
俞智勇
黄芝英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Baotai Biotechnology Co ltd
Original Assignee
Hangzhou Arnold Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Arnold Biomedical Technology Co ltd filed Critical Hangzhou Arnold Biomedical Technology Co ltd
Priority to CN202110060670.2A priority Critical patent/CN112876458B/zh
Priority to CN202110060576.7A priority patent/CN112876411A/zh
Priority to CN202110060679.3A priority patent/CN112876463B/zh
Publication of CN112313220A publication Critical patent/CN112313220A/zh
Application granted granted Critical
Publication of CN112313220B publication Critical patent/CN112313220B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

本发明提供了一种式(I)化合物及其药物组合物，以及使用式(I)化合物预防和/或治疗免疫相关病症的方法。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080003296.6A 2019-02-21 2020-02-20 Pd-l1拮抗剂化合物 Active CN112313220B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202110060670.2A CN112876458B (zh) 2019-02-21 2020-02-20 细胞程序性死亡-配体-1拮抗剂化合物
CN202110060576.7A CN112876411A (zh) 2019-02-21 2020-02-20 化合物及其在合成pdl1拮抗剂类药物分子中的应用
CN202110060679.3A CN112876463B (zh) 2019-02-21 2020-02-20 一种制备pd-l1拮抗剂的中间体及其制备方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019101303131 2019-02-21
CN201910130313 2019-02-21
CN201910695768 2019-07-30
CN2019106957688 2019-07-30
PCT/CN2020/075938 WO2020169058A1 (zh) 2019-02-21 2020-02-20 Pd-l1拮抗剂化合物

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202110060576.7A Division CN112876411A (zh) 2019-02-21 2020-02-20 化合物及其在合成pdl1拮抗剂类药物分子中的应用
CN202110060679.3A Division CN112876463B (zh) 2019-02-21 2020-02-20 一种制备pd-l1拮抗剂的中间体及其制备方法
CN202110060670.2A Division CN112876458B (zh) 2019-02-21 2020-02-20 细胞程序性死亡-配体-1拮抗剂化合物

Publications (2)

Publication Number Publication Date
CN112313220A true CN112313220A (zh) 2021-02-02
CN112313220B CN112313220B (zh) 2023-11-03

Family

ID=72143312

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202110060576.7A Pending CN112876411A (zh) 2019-02-21 2020-02-20 化合物及其在合成pdl1拮抗剂类药物分子中的应用
CN202110060670.2A Active CN112876458B (zh) 2019-02-21 2020-02-20 细胞程序性死亡-配体-1拮抗剂化合物
CN202080003296.6A Active CN112313220B (zh) 2019-02-21 2020-02-20 Pd-l1拮抗剂化合物
CN202110060679.3A Active CN112876463B (zh) 2019-02-21 2020-02-20 一种制备pd-l1拮抗剂的中间体及其制备方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202110060576.7A Pending CN112876411A (zh) 2019-02-21 2020-02-20 化合物及其在合成pdl1拮抗剂类药物分子中的应用
CN202110060670.2A Active CN112876458B (zh) 2019-02-21 2020-02-20 细胞程序性死亡-配体-1拮抗剂化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110060679.3A Active CN112876463B (zh) 2019-02-21 2020-02-20 一种制备pd-l1拮抗剂的中间体及其制备方法

Country Status (6)

Country Link
US (1) US20220227733A1 (zh)
EP (1) EP3929188A4 (zh)
JP (1) JP7281834B2 (zh)
CN (4) CN112876411A (zh)
TW (1) TW202045487A (zh)
WO (1) WO2020169058A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066423A (zh) * 2019-12-26 2022-09-16 杭州阿诺生物医药科技有限公司 Pd-l1拮抗剂化合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104744A1 (en) 2021-12-06 2023-06-15 Helmholtz-Zentrum Dresden-Rossendorf E.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009505A1 (en) * 2016-07-08 2018-01-11 Bristol-Myers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
WO2018195321A1 (en) * 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN109665968A (zh) * 2017-10-16 2019-04-23 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015037A2 (en) * 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
MX2016002544A (es) * 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3459925B1 (en) * 2016-05-23 2021-08-11 Tianjin Chase Sun Pharmaceutical Co., Ltd. Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009505A1 (en) * 2016-07-08 2018-01-11 Bristol-Myers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
WO2018195321A1 (en) * 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN109665968A (zh) * 2017-10-16 2019-04-23 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066423A (zh) * 2019-12-26 2022-09-16 杭州阿诺生物医药科技有限公司 Pd-l1拮抗剂化合物
CN115066423B (zh) * 2019-12-26 2024-02-02 厦门宝太生物科技股份有限公司 Pd-l1拮抗剂化合物

Also Published As

Publication number Publication date
CN112876411A (zh) 2021-06-01
WO2020169058A1 (zh) 2020-08-27
TW202045487A (zh) 2020-12-16
CN112876463B (zh) 2022-11-11
CN112313220B (zh) 2023-11-03
JP2022501397A (ja) 2022-01-06
CN112876463A (zh) 2021-06-01
EP3929188A4 (en) 2022-10-12
CN112876458B (zh) 2022-10-04
EP3929188A1 (en) 2021-12-29
JP7281834B2 (ja) 2023-05-26
CN112876458A (zh) 2021-06-01
US20220227733A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
CN111386275B (zh) 高活性sting蛋白激动剂
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
WO2022089454A1 (zh) 一种高活性Wnt通路抑制剂化合物
WO2019158070A1 (zh) A2a和/或a2b受体拮抗剂
CN112313220A (zh) Pd-l1拮抗剂化合物
US20230399327A1 (en) High activity hpk1 kinase inhibitor
CN115066423A (zh) Pd-l1拮抗剂化合物
CN112028891B (zh) 腺苷受体拮抗剂
TWI768781B (zh) 轉化生長因子－β受體抑制劑
CN112625050B (zh) 一种a2a和/或a2b受体抑制剂的制备方法
CN111440148B (zh) 一种腺苷受体拮抗剂的制备方法
LU505117B1 (en) A pan-KRAS inhibitor compound
WO2024022365A1 (zh) 一种Wnt通路抑制剂化合物
TWI810547B (zh) Pd-l1拮抗劑化合物
JP7284161B2 (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
WO2024054602A1 (en) Heterobifunctional compounds and methods of treating disease
WO2023143546A1 (zh) Wnt通路抑制剂化合物
CN117396482A (zh) 一种Wnt通路抑制剂化合物
WO2022199561A1 (zh) Hpk1激酶抑制剂化合物
CN117903169A (zh) 一种pan-KRAS抑制剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211125

Address after: 361000 floor 3-5, No. 188, Pingcheng South Road, Haicang street, Haicang District, Xiamen City, Fujian Province

Applicant after: Xiamen Baotai Biotechnology Co.,Ltd.

Address before: 311100 Building 8, 1008 Xiangxiang street, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province

Applicant before: Hangzhou Arnold Biomedical Technology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant